Nevro. Corp. closed the acquisition of privately held Vyrsa Technologies Inc., adding the company’s V1 implant for sacroiliac (SI) joint fusion to its product line for chronic pain. Nevro paid $40 ...

Nevro's high-frequency neurostimulation cuts diabetic neuropathy pain by 80% in 2-year study By Andrea Park Aug 16, 2023 11:46am Nevro spinal cord stimulation neurostimulation diabetic neuropathy ...

This was also ~18% of the company's permanent implant volumes. It pulled this to another operating loss of $25.8mm and a net loss of $0.69/share, flat on Q2 FY'22.

Earnings Estimate Revisions for Nevro This maker of an electrical implant that treats leg and back pain is expected to earn -$2.40 per share for the fiscal year ending December 2024, which ...

Nevro is a company that has developed a spinal cord stimulation implant to treat chronic pain. See why I will remain on the sidelines on NVRO stock for now.

The maker of an electrical implant that treats leg and back pain posted revenue of $96.9 million in the period, also beating Street forecasts. Seven analysts surveyed by Zacks expected $93.1 million.

Financial Position Nevro exited second-quarter 2022 with cash and cash equivalents, and short-term investments of $310.8 million compared with $323.6 million at the end of first quarter. Long-term ...